KeepsvsMusely Hair Formula Rx

Keeps itself is a telehealth service, not a drug; an online clinician reviews your intake and prescribes generic medications shipped to your door. The actual hair regrowth comes from two well-studied ingredients. Finasteride is an oral Type II 5-alpha-reductase inhibitor that lowers scalp DHT, the hormone that miniaturizes genetically susceptible follicles, thereby slowing loss and allowing some regrowth. Minoxidil is a topical vasodilator thought to prolong the follicle's growth (anagen) phase and increase blood flow to follicles, helping produce thicker hair; its exact mechanism in hair growth is still not fully understood. Keeps also offers a compounded once-daily topical finasteride/minoxidil gel and foam (0.25% finasteride, 5% minoxidil), ketoconazole 2% shampoo, and may offer dutasteride for some patients.

Musely Hair Formula Rx is a custom prescription that a compounding pharmacy makes after a telehealth provider reviews your photos and medical history. The topical "Hair Solution" (Classic) typically blends minoxidil 8% (widens scalp blood vessels and extends the follicle's growth phase), dutasteride (blocks both types of 5-alpha-reductase, the enzyme that creates DHT, the hormone that miniaturizes follicles in pattern hair loss), spironolactone (an additional anti-androgen), tretinoin (intended to boost minoxidil penetration), and ketoconazole plus hydrocortisone (to calm scalp inflammation and irritation). A "Modern" topical adds ingredients such as latanoprost, caffeine, and melatonin. The oral "Hair Pill" pairs low-dose oral minoxidil with dutasteride to suppress DHT systemically, and women's formulas may include spironolactone. The goal is to attack hair loss through multiple pathways at once. Note that Musely's topical uses dutasteride rather than finasteride; both block DHT, but dutasteride is more potent and has a much longer half-life.

The medications Keeps prescribes have strong evidence; Keeps has not published its own large clinical trials. In a multinational study of men with male pattern hair loss, oral finasteride 1 mg daily produced durable hair-count improvement over five years while placebo users progressively lost hair (p<0.001 for all endpoints; PubMed 11809594). Earlier pivotal trials showed roughly two-thirds of finasteride users had visible improvement versus continued loss on placebo. For minoxidil, a 48-week randomized trial in 393 men found 5% topical minoxidil significantly superior to 2% and placebo in non-vellus hair count, and a separate 16-week foam trial in 352 men showed significant hair-count gains versus placebo (P<.0001). Smaller studies suggest combining finasteride and minoxidil may outperform either alone. Benefits require continuous use; stopping reverses gains within months.

The core actives are well-supported, though Musely's specific compounded formula has not been tested in its own published controlled trial, so efficacy is inferred from its ingredients rather than the branded product. Topical minoxidil is the only FDA-approved topical for androgenetic alopecia (oral finasteride and oral minoxidil's relatives aside, minoxidil is the topical standard): in the pivotal Olsen 2002 randomized trial of 393 men, 5% topical minoxidil produced a mean increase of about 18.6 non-vellus hairs/cm2 versus about 3.9 with placebo at 48 weeks, with roughly 60% of users rated improved on global photographic assessment versus about 23% on placebo. A 2025 systematic review and meta-analysis of 7 randomized trials (N=396) found topical minoxidil-finasteride combinations beat minoxidil alone, with a mean difference of about 9 more hairs/cm2 in density and significantly better global photographic assessment. A separate small 2025 RCT (N=40) found topical 0.1% finasteride plus 5% minoxidil performed about the same as minoxidil alone over a short 12-week window, a reminder that the added DHT-blocker benefit can take longer to show and that Musely's stronger dutasteride-based formula has not been individually validated.

Minoxidil's common side effects are local: scalp itching, dryness, flaking, or irritation, plus possible temporary "shedding" in the first weeks. Unwanted facial or body hair can occur if it spreads beyond the scalp. Finasteride's notable risks are sexual: in Merck's Phase III trials about 1.3-1.8% of men reported decreased libido, erectile dysfunction, or ejaculation problems (versus roughly 0.7-1.3% on placebo), usually reversible after stopping. A debated but reported condition, "post-finasteride syndrome," describes sexual or mood symptoms persisting after discontinuation. The FDA-approved finasteride 1 mg (Propecia) label lists depression and, since an August 2022 update, suicidal ideation and behavior among postmarketing adverse reactions. Finasteride also lowers PSA, and the label notes a possible increased risk of high-grade prostate cancer. Seek medical care for mood changes, persistent sexual dysfunction, breast lumps or tenderness, or signs of an allergic reaction.

Common local effects from the topical include scalp itching, dryness, flaking, redness, stinging, and a temporary increase in shedding in the first 4-12 weeks. Minoxidil can cause unwanted facial hair if it migrates and, rarely, dizziness, fluid retention, or palpitations. The serious concern is the DHT blocker: in April 2025 the FDA issued a safety alert after receiving 32 reports (2019-2024) of systemic adverse events from compounded topical finasteride, including decreased libido, erectile dysfunction, depression, anxiety, suicidal ideation, brain fog, fatigue, and insomnia, some of which persisted after stopping. Musely's topical uses dutasteride rather than finasteride, but dutasteride is a more potent, longer-acting 5-alpha-reductase inhibitor and is also absorbed through the skin, so the same class of systemic risks reasonably applies and has not been ruled out. Spironolactone can cause menstrual changes, breast tenderness, and elevated potassium. Stop and seek medical care for mood changes, suicidal thoughts, chest pain, or breathing problems.

As of 2026, Keeps positions itself as budget-friendly: individual plans often start around $10-25 per month (minoxidil at the low end, generic finasteride roughly $17-25), with combination and compounded multi-ingredient formulas costing more, plus a roughly $5 shipping fee per order. Longer 6- or 12-month commitments usually lower the per-month price, and the online consultation is typically free or low-cost. Insurance generally does not cover cosmetic hair-loss treatment. Because these are generics, it's worth comparing: a GoodRx coupon for generic finasteride or minoxidil at a local pharmacy can sometimes match or beat subscription pricing, though you'd manage the prescription and refills yourself. Keeps' parent company agreed to be acquired in late 2025, so verify current prices on the Keeps website before subscribing.

As of 2026, Musely hair treatments are out-of-pocket; insurance generally does not cover compounded cosmetic-hair prescriptions, though FSA/HSA cards may be accepted. Expect roughly $95-$155 for a multi-month (about three-month) supply depending on the formula and whether you choose auto-refill (cheaper, advertised at up to ~30% off) or a one-time purchase, plus a one-time ~$20 doctor-visit fee that covers a one-year prescription and a 60-day consultation period. Auto-refill subscriptions can be paused or canceled before shipment at no cost. Musely advertises a 60-day money-back guarantee, but it generally does not apply to prescription hair treatments (which the company states are nonrefundable), so do not count on a refund for these products. Generic 5% minoxidil bought over the counter is far cheaper if you do not need the compounded combination.

Keeps is designed for adult men (18+) with hereditary male pattern hair loss (androgenetic alopecia), and works best on early-to-moderate thinning at the crown and hairline rather than long-established bald areas. Finasteride is FDA-indicated for men only and is contraindicated in women who are or may become pregnant, who should not handle crushed or broken tablets, because it can cause genital abnormalities in a male fetus. Men with a history of depression or mood disorders, men planning to father children, or those with prostate-cancer concerns should discuss finasteride carefully with a clinician, since it lowers PSA levels (affecting prostate-cancer screening) and its label notes that 5-alpha-reductase inhibitors may increase the risk of high-grade prostate cancer. Men who want to avoid hormonal side effects entirely can use minoxidil alone.

Intended for adults with hormonal or pattern hair loss (androgenetic alopecia), general thinning, telogen effluvium, or postpartum shedding, after a clinician approves the prescription. It is not for scarring or autoimmune hair loss (e.g., alopecia areata), which need a different medical evaluation. Women who are pregnant, trying to conceive, or breastfeeding must avoid dutasteride and spironolactone (risk of harm to a developing fetus, including feminization of a male fetus), and tretinoin is also contraindicated in pregnancy; women should not even handle the dutasteride-containing products in these situations. Men concerned about sexual or mood side effects, and anyone with a history of depression or suicidal thoughts, should weigh the DHT-blocker risks carefully with the prescriber. People with low blood pressure, heart conditions, or kidney problems should flag minoxidil and spironolactone use, and you should always confirm a diagnosis with a clinician before starting.